Progesterone

See our Evidence Standards for how we grade the research below.

What It Is

Progesterone is a steroid hormone produced primarily by the ovaries after ovulation and, during pregnancy, by the placenta. Micronized progesterone, the form used in bioidentical hormone therapy, is structurally identical to what the body produces. In menopausal hormone therapy, its best-known clinical role is protecting the uterine lining from the proliferative effects of estrogen in women who still have a uterus, but it also crosses the blood-brain barrier and is metabolized into allopregnanolone, a neurosteroid that acts on GABA-A receptors, the same receptor system targeted by benzodiazepines, which is the mechanism behind its commonly reported calming and sleep effects.

Progesterone and progestins are not the same molecule. Progestins (medroxyprogesterone acetate, norethindrone, and others) are synthetic compounds designed to activate progesterone receptors, but they differ structurally from progesterone itself and bind other steroid receptors too, which is part of why their side-effect and risk profiles differ. Much of the research that shaped public concern about "progestin" side effects, including from the Women's Health Initiative, used medroxyprogesterone acetate specifically, not micronized progesterone. The studies below distinguish which molecule was actually tested.
A quick note on "normal." Progesterone reference ranges depend heavily on where a woman is in her cycle or on menopausal status, and a level that clears a broad population range can still be too low, relative to estrogen, to give a patient the sleep, mood, or cycle-regularity benefits her own physiology is capable of. A lab number alone does not capture that balance; symptoms and the estrogen-to-progesterone relationship both factor into the clinical picture here. More on this idea across every hormone on this site is in the Cellular Medicine framework.

The Evidence

Asi N, Mohammed K, Haydour Q, et al. "Progesterone vs. Synthetic Progestins and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis." Systematic Reviews. 2016 Jul 26;5:121. PMID: 27456847. Systematic review and meta-analysis screening 3,410 citations, ultimately including two cohort studies and one population-based case-control study, together covering 86,881 postmenopausal women (mean age 59, follow-up 3-20 years). When combined with estrogen, progesterone was associated with significantly lower breast cancer risk than synthetic progestins (relative risk 0.67, 95% CI 0.55-0.81). The authors noted no data were available on cardiovascular events for this specific comparison, and rated the overall risk of bias in the included cohort studies as moderate.

Meta-analysis of 3 observational studies (N=86,881) Endpoint: Clinical outcome (breast cancer incidence)

The Writing Group for the PEPI Trial. "Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA. 1995 Jan 18;273(3):199-208. PMID: 7807658. Three-year, multicenter, randomized, double-blind, placebo-controlled trial. 875 healthy postmenopausal women aged 45-64 were randomized to placebo, CEE alone, or CEE combined with one of three progestin regimens, including cyclic micronized progesterone. Both medroxyprogesterone acetate and micronized progesterone improved cardiovascular risk-factor markers relative to placebo, but micronized progesterone preserved more of unopposed estrogen's HDL-cholesterol-raising benefit than medroxyprogesterone acetate did, which blunted it more. This trial measured risk-factor biomarkers, not actual cardiovascular events.

RCT (N=875) Endpoint: Surrogate (lipid and coagulation markers, not cardiac events)

Nolan BJ, Liang B, Cheung AS. "Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Data." Journal of Clinical Endocrinology & Metabolism. 2021;106(4):e942-e951. PMID: 33245776. Systematic review and meta-analysis of randomized controlled trials, predominantly in postmenopausal women, finding that micronized progesterone improved various sleep outcomes compared with placebo or comparators. The authors noted that evidence specifically for micronized progesterone used alone (monotherapy), rather than combined with estrogen, and evidence using objective measures like polysomnography rather than questionnaires alone, remained limited, and called for further research on both fronts.

Meta-analysis of RCTs Endpoint: Clinical outcome (sleep quality measures)

What's Reported in Practice

Anecdotal / clinical experience, not yet trial-tested

Beyond sleep specifically, patients commonly report reduced anxiety, a calmer mood, and improved tolerance of estrogen therapy overall when progesterone is added to their regimen. These reports line up well with the GABA-A/allopregnanolone mechanism and with the sleep-trial evidence above, so we think they're a credible signal, though calming and anxiety effects specifically, as distinct from sleep quality, haven't been isolated as a primary endpoint in a trial of the size and rigor of the sleep meta-analysis above.

What the Research Doesn't Yet Show

This is where we're most eager to see more research investment, not a mark against progesterone. The breast-cancer comparison against synthetic progestins, while encouraging and directionally consistent with the biology, rests entirely on observational data, no randomized trial has directly compared progesterone to a synthetic progestin on breast cancer incidence, largely because a trial of that size and duration would be enormous to run. The PEPI trial's cardiovascular findings are for risk-factor markers, not actual heart attacks or strokes, so the clinical significance of micronized progesterone's more favorable lipid profile compared with medroxyprogesterone acetate hasn't been confirmed with hard outcome data. And the sleep evidence, while genuinely solid at the meta-analysis level, is thinner for progesterone used alone rather than combined with estrogen, and for objective sleep measures rather than questionnaires, exactly the kind of well-designed trial this field needs next.

Compounded and FDA-approved formulations both exist for progesterone; specific product, route, and dose are individualized based on your history, whether you have a uterus, and your goals, and discussed at your visit.

Next Step

This page covers mechanism and evidence. Formulation, route, dose, and whether this is appropriate for you are individual clinical decisions made with your provider.

Already a patient? Bring this up at your next 4Ever Young visit. Have a question first?

Linktree DM on Instagram Email Dr. Wilcox